MIR543

Summary

MIR543 (microRNA 543, HGNC:33664) is a microRNA gene on chromosome 14q32.31.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 100126335 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:33664
Approved symbol	MIR543
Name	microRNA 543
Location	14q32.31
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-543
Ensembl gene	ENSG00000212040
Ensembl biotype	miRNA
Entrez	100126335
RNAcentral	URS000075CC43 — miRNA, 78 nt, 15 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000390751

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000390751 — 1 exons

Exon	Start	End
ENSE00001508428	101031987	101032064

Expression profiles

Bgee: expression breadth broad, 41 present calls, max score 90.75.

Top tissues by expression

41 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
adrenal tissue	UBERON:0018303	90.75	gold quality
bone marrow	UBERON:0002371	80.11	gold quality
stomach	UBERON:0000945	79.59	gold quality
heart	UBERON:0000948	79.41	gold quality
intestine	UBERON:0000160	78.77	gold quality
colon	UBERON:0001155	76.54	gold quality
heart left ventricle	UBERON:0002084	75.35	gold quality
blood	UBERON:0000178	73.29	gold quality
left adrenal gland cortex	UBERON:0035825	71.98	gold quality
prefrontal cortex	UBERON:0000451	69.41	gold quality
Ammon’s horn	UBERON:0001954	69.37	gold quality
lung	UBERON:0002048	69.10	gold quality
liver	UBERON:0002107	68.36	gold quality
endometrium	UBERON:0001295	67.41	gold quality
left ovary	UBERON:0002119	67.33	gold quality
esophagus mucosa	UBERON:0002469	66.78	gold quality
substantia nigra	UBERON:0002038	66.49	gold quality
hypothalamus	UBERON:0001898	66.09	gold quality
transverse colon	UBERON:0001157	65.57	gold quality
Brodmann (1909) area 9	UBERON:0013540	65.50	gold quality
body of pancreas	UBERON:0001150	65.35	gold quality
spleen	UBERON:0002106	64.94	gold quality
tibial artery	UBERON:0007610	64.59	gold quality
vagina	UBERON:0000996	63.91	gold quality
right adrenal gland cortex	UBERON:0035827	63.85	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	63.52	gold quality
right frontal lobe	UBERON:0002810	63.14	gold quality
caudate nucleus	UBERON:0001873	62.79	gold quality
left uterine tube	UBERON:0001303	62.65	gold quality
brain	UBERON:0000955	62.46	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.44

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• Data indicate that miR-145 and miR-543 were down-regulated in mammospheres. (PMID:22752669)
• miR-543 significantly decreased in mesenchymal stem cells aging process. (PMID:25465621)
• Study shows that MiR-543 inhibits translation of MMP7 through binding to the 3’-UTR of MMP7 mRNA in ovarian cancer. PLGF suppresses miR-543, which activates MMP7-mediated cancer invasion. (PMID:26402225)
• In summary, our study suggested that the downregulation of the miR-543 could alleviate the insulin resistance via the modulation of the SIRT1 expression. (PMID:26562529)
• Our results identify a new regulatory mechanism of miR-543 on SIRT1 expression in gastric cancer, and raise the possibility that the miR-543/SIRT1 pathway may serve as a potential target for the treatment of gastric cancer. (PMID:26612257)
• miR-543 was constitutively up-regulated in colorectal cancer tissues and its over-expression promoted tumor cell migration and invasion. Moreover, PTEN was identified as a direct target of miR-543. (PMID:27148794)
• Mechanistically, miR-543 inhibited PRMT9-enhanced cell oxidative phosphorylation, while miR-543 depletion promoted PRMT9-increased HIF-1alpha instability and inhibited glycolysis in osteosarcoma (OS) cells. Clinically, miR-543 expression was negatively correlated with PRMT9 expression in OS tissues. (PMID:27911265)
• Findings collectively demonstrate that microRNA-543 exerts its oncogene function by directly targeting BRCA1-interacting protein 1 in cervical cancer. (PMID:28231728)
• The study demonstrates that miR-543 promotes the proliferation and metastasis of prostate cancer via targeting RKIP. (PMID:28245474)
• miR-543 may function as a tumor suppressor in glioma and may serve as a future therapeutic target in therapy for patients with glioma (PMID:28627653)
• miR-543 serves as a tumor suppressor in glioblastoma multiforme through ADAM9 regulation. (PMID:28849046)
• Overexpression of miR-543 markedly promoted the proliferation and invasion of clear cell renal cell carcinoma. (PMID:29101805)
• miR-543 was capable of directly targeting the 3’-UTR of PLA2G4A. (PMID:30071514)
• Results suggest for the first time a role for miR-370 and miR-543 and its target DNAJB1 in the pathogenesis of spinocerebellar ataxia type 3 (SCA3). In human neuronal cultures derived from SCA3 patient-specific induced pluripotent stem cell (iPSC) lines, miR-370 and miR-543 levels are upregulated, while DNAJB1 expression is concurrently reduced. (PMID:30086154)
• indicate that interleukin-33 (IL-33) was a target gene of miR-543, and that a binding site of miR-543 was identified in the 3’ untranslated region (3’UTR) of IL-33. (PMID:30146845)
• miR-543 plays an important role during embryo implantation process and is associated with endometrial receptivity. Downregulation of miR-543 may affect embryo implantation, resulting in the pathogenesis of endometriosis-related infertility. (PMID:30231774)
• Overexpression of miR-543 in cervical cancer cell lines remarkably inhibited cell proliferation, invasion and migration, caused cell cycle arrest, promoted apoptosis in vitro, and suppressed tumor growth in vivo, whereas miR-543 inhibitor showed the opposite effect. (PMID:30710498)
• Results indicate that miR-543 might be a target to increase the sensitivity of colorectal cancer (CRC) cells to 5-fluorouracil (5-FU) through the PTEN/PI3K/AKT pathway. (PMID:30842340)
• inhibition of miR-543 was found to play a tumor suppressive role in PA through the down-regulation of Wnt/beta-catenin pathway by negatively regulating Smad7 (PMID:30973065)
• results suggested that SNHG7 is a potential molecular target for attenuating high-glucose-induced angiogenesis in the diabetic retinopathy through regulation of the miR-543-mediated SIRT1/VEGF pathway (PMID:31056258)
• miR-543 can target Wnt protein to inhibit the activity of Wnt signaling pathway (PMID:31204929)
• High miR543 expression is associated with oral squamous cell carcinoma. (PMID:31322243)
• Morphine at 10(-6) mol/l could benefit miR-543 expression to inhibit MARCKS expression. (PMID:31373006)
• SIRT1-targeted miR-543 autophagy inhibition and epithelial-mesenchymal transition promotion in Helicobacter pylori CagA-associated gastric cancer. (PMID:31423013)
• miR-543-induces proliferation and invasion of nasopharygeal carcinoma. (PMID:31428943)
• Linc-PINT acted as a tumor suppressor by sponging miR-543 and miR-576-5p in esophageal cancer. (PMID:31464068)
• miR217 and miR543 downregulation mitigates inflammatory response and myocardial injury in children with viral myocarditis by regulating the SIRT1/AMPK/NFkappaB signaling pathway. (PMID:31894309)
• miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2. (PMID:31941838)
• LINC-PINT alleviates lung cancer progression via sponging miR-543 and inducing PTEN. (PMID:31981466)
• miR-543 might promote ovarian cancer cell proliferation and invasion by targeting TWIST1. (PMID:32148011)
• Knockdown of long non-coding RNA PVT1 induces apoptosis of fibroblast-like synoviocytes through modulating miR-543-dependent SCUBE2 in rheumatoid arthritis. (PMID:32293498)
• Long Noncoding RNA SNHG10 Sponges miR-543 to Upregulate Tumor Suppressive SIRT1 in Nonsmall Cell Lung Cancer. (PMID:32319822)
• MiR-543 promotes tumorigenesis and angiogenesis in non-small cell lung cancer via modulating metastasis associated protein 1. (PMID:32410569)
• The role of miR-543 in human cancerous and noncancerous diseases. (PMID:32542683)
• MiR-543 inhibits proliferation and metastasis of human colorectal cancer cells by targeting PLAS3. (PMID:32964969)
• Higher miR-543 levels correlate with lower STK31 expression and longer pancreatic cancer survival. (PMID:33128354)
• miR-543 Inhibits the Occurrence and Development of Intrauterine Adhesion by Inhibiting the Proliferation, Migration, and Invasion of Endometrial Cells. (PMID:33860034)
• LncRNA-LINC01089 inhibits lung adenocarcinoma cell proliferation and promotes apoptosis via sponging miR-543. (PMID:33892399)
• MicroRNA-543-3p down-regulates inflammation and inhibits periodontitis through KLF6. (PMID:33955459)
• CircSOS2 promotes cervical squamous cell carcinoma by regulation of proliferation, cell cycle, apoptosis, migration, invasion, and glycolysis by targeting miR-543/FNDC3B axis. (PMID:34023283)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.